Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
ATXS Astria Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: ATXS
Price (delayed)
$3.97
Market cap
$224.04M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.87
Enterprise value
$174.72M
Highlights
Astria Therapeutics's debt has decreased by 5% QoQ
The company's EPS rose by 22% YoY but it fell by 11% QoQ
ATXS's quick ratio is down by 49% YoY
The net income has declined by 32% year-on-year and by 15% since the previous quarter
Key stats
What are the main financial stats of ATXS
Market
Valuations
Earnings
Shares outstanding
56.43M
Market cap
$224.04M
Enterprise value
$174.72M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.77
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$124.4M
Net income
-$108.04M
EBIT
-$108.04M
EBITDA
-$108.04M
Free cash flow
-$96.46M
Per share
Balance sheet
Liquidity
EPS
-$1.87
EPS diluted
-$1.87
Free cash flow per share
-$1.66
Book value per share
$5.13
Revenue per share
$0
TBVPS
$5.35
Total assets
$310.39M
Total liabilities
$21.1M
Debt
$5.06M
Equity
$289.29M
Working capital
$285.54M
Debt to equity
0.02
Current ratio
17.39
Quick ratio
16.93
Net debt/EBITDA
0.46
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-31.3%
Return on equity
-33.3%
Return on invested capital
-41%
Return on capital employed
-36.9%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ATXS stock price
How has the Astria Therapeutics stock price performed over time
Intraday
1.79%
1 week
-10.18%
1 month
-5.92%
1 year
-58.17%
YTD
-55.59%
QTD
-25.66%
Financial performance
How have Astria Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$124.4M
Net income
-$108.04M
Gross margin
N/A
Net margin
N/A
The operating income has declined by 33% year-on-year and by 12% since the previous quarter
The net income has declined by 32% year-on-year and by 15% since the previous quarter
Price vs fundamentals
How does ATXS's price correlate with its fundamentals
Growth
What is Astria Therapeutics's growth rate over time
Valuation
What is Astria Therapeutics stock price valuation
P/E
N/A
P/B
0.77
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS rose by 22% YoY but it fell by 11% QoQ
The P/B is 49% lower than the last 4 quarters average of 1.5 and 41% lower than the 5-year quarterly average of 1.3
Astria Therapeutics's equity has decreased by 21% YoY and by 9% QoQ
Efficiency
How efficient is Astria Therapeutics business performance
The ROIC has soared by 50% YoY but it has decreased by 9% QoQ
Astria Therapeutics's return on equity has decreased by 22% QoQ
ATXS's ROA is down by 20% QoQ
Dividends
What is ATXS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ATXS.
Financial health
How did Astria Therapeutics financials performed over time
ATXS's total liabilities has soared by 91% year-on-year but it is down by 9% since the previous quarter
ATXS's quick ratio is down by 49% YoY
Astria Therapeutics's debt is 98% lower than its equity
Astria Therapeutics's equity has decreased by 21% YoY and by 9% QoQ
Astria Therapeutics's debt has decreased by 5% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.